



FORM 13
 (See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
 SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

- Name of Inspector from whom received : R. Vanlalsiama,
Asst Director (F&D),
CMO Office, Lunglei.
- Serial No. and date of Inspector's memorandum : 8 , Date: 12-DEC-2024
- Number of Sample : MS-5
- Date of receipt : 23-DEC-2024
- Names of drugs purporting to be contained in the sample : CIPROFLOXACIN TABLETS IP 250 mg (Ciprodac 250)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg.	Date of Exp.	Mfg. By
LSD/GUW/2024-25/1586	GUW/LS/2024-25/1601	CT24001	Feb-2024	Jan-2027	CADILA PHARMACEUTICALS LIMITED, 1389, Dholka-382225, Dist. Ahmedabad

6. Condition of seals on : Seals were intact & identical to the
 [the packet or on portion of sample or container] Specimen impression of the seal received from Drugs Inspector

7. Result of test or analysis with protocols or test or analysis applied : Please see below

Date of Testing : From 20-Jan-2025 To 24-Jan-2025

COMPOSITION : Each film-coated tablet contains:
 Ciprofloxacin Hydrochloride IP
 equivalent to Ciprofloxacin 250 mg

Protocol Applied : I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	White, round, bi-convex, film coated tablet having scored on one side in blister strip.	NA
2	Identification	Gives positive test for Ciprofloxacin.	NA
3	Average weight	0.3365 g	NA
4	Uniformity of weight	Passes the test.	NA
5	Dissolution	Complies.	NLT 80 %

say

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
1	Ciprofloxacin Hydrochloride equivalent to Ciprofloxacin	253.01 mg/Tablet	250 mg/Tablet	101.204	90 % to 110 %	I.P. 2022

In the opinion of the undersigned the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conforms to I.P. with respect to the above tests only.

Date: 27-JAN-2025



GOVERNMENT ANALYST
Amar Jyoti Chamuah
Government Analyst
R.D.T.L., Guwahati-22

END OF REPORT

